OXLUMO
Active substance: lumasiran
INJECTION, SOLUTION · LUMASIRAN SODIUM 94.5 mg/.5mL
United StatesActive
Marketing holder: Alnylam Pharmaceuticals, Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- LUMASIRAN SODIUM · 94.5 mg/.5mL
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1208c-c61d-74f3-9168-f960af9b81a4;count=1 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 71336-1002
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- SUBCUTANEOUS
Sources
- product · openFDA NDC · 71336-1002 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 71336-1002 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 71336-1002 · Verified 2026-10-09 · open in source